Audit: QRS - Noopept for Health & Longevity

Audit conducted on 04/09/2026 21:06 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	84
Failed	0
N/A	9
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) x 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Every populated span traces to ER text: at-a-glance to Conclusion; action/time cells to Therapeutic Protocol, Practical Considerations, Expected Benefits and Discontinuation & Cycling; gates to Key Interactions & Contraindications; monitoring rows and cadence to Monitoring Protocol & Defining Success.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	Cautious ER phrasing is carried verbatim, e.g. marker_9_target “No established target; track change from the individual’s own baseline” and risks_speculative “immune modulation of uncertain direction”.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Severity is preserved throughout; “Alcohol: absolute avoidance” matches the ER’s “Absolute avoidance per the manufacturer’s insert”, and every contraindication remains a contraindication.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Categories are respected: action_3 draws on the Therapeutic Protocol bullet “Baseline biomarkers” rather than the similarly named Benefit-Modifying Factors bullet, and no modifying factor appears in the gates.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	The QRS carries no PMIDs, citations, expert names, NCT identifiers or brand names; the drug names in caution_items are the ER’s own example lists.
1.6	The QRS does not introduce new attributions.	🟢	No attributions of any kind are present in the QRS.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	The sheet mirrors the ER’s evidence-first, skeptical register — unreplicated Russian data, mislabeled retail product, blood-pressure signal.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Thresholds, ranges and decision gates are given plainly, giving the reader the means to test the intervention on themselves rather than a verdict alone.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	All content is stated as noun phrases and observations; no directive is issued in the document’s own voice.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	The monitoring cadence and protocol cells describe what was done and measured in the source, not what the reader is to do.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No instance of “should”, “must”, “recommend”, “advise” or an imperative verb appears anywhere in the rendered body.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronoun occurs in the document.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms are confined to the monitoring table, where the marker names are the measurements themselves; elsewhere plain renderings are used (e.g. “activating brain-rhythm signature”).
2.8	Information is presented in a concise and very compact manner	🟢	Consequences, mitigations, citations and magnitudes from the ER bullets are stripped; entries are reduced to the operative fact.
2.9	It DOES NOT address the reader directly	🟢	Confirmed — no direct address anywhere in the body.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	The sheet assumes a reader who will run a 14-day home blood-pressure baseline and a validated cognitive screen before dosing.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Nine biomarkers, nightly qualitative tracking and a weekly blood-pressure cadence are presented without hedging about burden.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Optimal functional ranges are used rather than conventional laboratory cut-offs, which only serves a self-experimenting audience.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	action_3 and at_a_glance both foreground that no gain has been shown in unimpaired adults — the decisive point for this audience specifically.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	The string “anti-aging” does not occur in the document; the title uses “Health & Longevity”.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	Formal terminology throughout (“hepatic impairment”, “therapeutic anticoagulation”, “hypersensitivity reactions”); no colloquial substitutes such as “pill” or “shot” appear.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: * Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment” * Gate headings: “Contraindications”, “Key Interactions” * Tier labels: “High”, “Medium”, “Low”, “Speculative” * Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All fixed strings are byte-identical to the template: headings at lines 440, 477, 519, 575, 592, 711; gate headings at 539 and 554; tier labels in the Benefits and Risks lists; column headers at 596–598.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	Every template variable is present; the repeatable marker_#_* and qualitative_item_# patterns are expanded to marker_1..9_* and qualitative_item_1..5.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	A structural diff against the template shows changes confined to variable content; the website="..." spans, the footer disclaimer, the stylesheet link and all CSS are untouched.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section relied on by the QRS is empty. The ER’s High-risk tier carries explanatory prose (“No risk reaches High: …”) rather than an empty-state phrase, and is handled under item 13.5.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	action_1..3_label reproduce the ER bullets “Standard clinical protocol”, “Best time of day” and “Baseline biomarkers”; all nine caution_items labels reproduce the ER interaction labels verbatim.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Every label with an ER counterpart is used unchanged; the Time-to-Effect cell labels have no corresponding ER bold label and are the minimal descriptors required by item 11.4.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji code point occurs in the file; the ER’s tier squares and the “⚠️ Conflicted” markers were correctly stripped.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	The sheet uses the template’s single-page layout unaltered, and every section is condensed rather than extended — the ~9,500-word ER is reduced to 776 visible words, with consequences, mitigations, magnitudes and citations dropped from every list.

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	The comment opens at line 2, immediately after <!doctype html> at line 1, and closes at line 14, ahead of the template comment at line 16.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- at line 3 and closing --- at line 13; the preceding descriptive text on line 2 sits outside the block.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	It is enclosed in an HTML comment and no value is repeated in the header, footer or any card.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	All values are trimmed and unquoted except duration: "00:03", which contains a colon and therefore requires quoting.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: noopept_2026-0904-1719_Opus_ER.md, matching the source ER’s own filename frontmatter.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.7.02, matching the version badge at the top of QRS.md.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0904-2052, in the required format.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” is a single word carrying no version or qualifier.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” is nickname plus version number, with no trailing qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9: qrs_filename: noopept_2026-0904-1719_Opus_QRS.html, matching the file on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all eleven keys; only the colon-bearing duration value is quoted.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: Noopept for Health & Longevity - Quick Reference Sheet, with the ampersand correctly encoded.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: Noopept for Health & Longevity, matching the ER canonical_topic.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: 09/04/2026, the correct MM/DD/YYYY rendering of 2026-0904-2052.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: Opus 5, matching the frontmatter value.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	The subline is the template’s, unchanged; the ER’s “Also known as” line was correctly not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	All three sentences condense the ER Conclusion: origin, the unreplicated impaired-only efficacy signal, the recorded harms, and the supply-quality problem.
7.2	[at_a_glance] is no longer than 60 words	🟢	59 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Each clause maps to a distinct Conclusion passage — the 1990s Russian origin, the memory and mood gains in impaired people, the absence of outside replication, the untested unimpaired case, the three harms, and the mislabeling.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronym or classification appears; “thinking”, “raised blood pressure”, “disrupted sleep” and “mislabeled” are all everyday terms.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial name, year, sample size or p-value appears; the studies are referred to only as “Russian studies”.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No numeric result of any kind appears in the summary.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All eight items come from that section’s “Populations who should avoid Noopept” list.
8.2	[stop_items] represent the Contraindications from the ER	🟢	All eight ER populations are represented, one to one, with none added and none dropped.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Lines 542–549: eight <li> elements inside the stop_items span.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Attributions and rationale are stripped (e.g. “per the manufacturer’s contraindication and the rodent developmental findings” dropped from the under-18 item); no dash-introduced trailing clause remains.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	All decision-relevant qualifiers survive: 160/100 mmHg, Child-Pugh Class B or C, eGFR below 60 mL/min/1.73 m², platelets below 100 × 10⁹/L, the 7-day surgical window and the valproate-monitoring exception.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER’s contraindication list uses no ranking notation; its comparison symbols denote numeric thresholds, not severity ordering.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The section is populated, and the ER does name eight such populations, so the condition for emptiness is correctly not invoked.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All nine items come from that section’s interaction bullets.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	Nine of the eleven ER bullets appear; “Anticonvulsants” is correctly omitted because the valproate case is already a contraindication, and “Statins and other transporter substrates” is marked “No action needed” in the ER and so is not an interaction that changes use.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Lines 557–565: nine <li> elements inside the caution_items span.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Every “Consequence is …” and “Mitigation is …” clause is stripped, leaving label plus example drugs; no dash-introduced trailing clause remains.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Every ER example list is carried through, including the “fish oil above 3 g daily” threshold and the “alpha-GPC, citicoline” choline donors.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER’s interaction bullets use no ranking notation inside parentheses.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The section is populated, and the ER does identify such interactions, so the condition for emptiness is correctly not invoked.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells derive from the ER Therapeutic Protocol bullets.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Dose and course length, timing of dosing, and the baseline-impairment precondition that determines whether any effect is obtainable — the three decisions that govern implementation.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER Therapeutic Protocol section contains twelve bullets, so all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine spans carry substantive content; labels and subs are the ER’s own wording and the values are faithful condensations of it.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Cognitive gain at 56 days, reduced drug-induced adverse reactions at one month, and occupational performance at two weeks — the only three benefits in the ER with a stated onset interval.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Ordered High, Medium then Low, matching the ER tiers of the underlying benefits (mild cognitive impairment; reduced neurotoxicity of concurrent drug therapy; occupational performance).
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies three distinct time-to-effect aspects, so all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine spans carry substantive content drawn from Practical Considerations, Expected Benefits and Discontinuation & Cycling.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER carries a dedicated “Time to effect” bullet plus dated outcomes, so the section is correctly retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All seven entries are the ER’s own benefit headings from that section.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans are present and populated at lines 521–532, matching the ER’s four tiers.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each entry is the bare ER heading; the “Magnitude:” paragraphs, trial descriptions and mechanism sentences are all dropped.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parenthetical content appears in any of the four spans.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four ER benefit tiers contain at least one entry, so no span needed hiding.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All eight entries are the ER’s own risk headings from that section.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans are present at lines 577–586.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each entry is the bare ER heading; the “Magnitude:” paragraphs, mechanism sentences and the “⚠️ Conflicted” marker are all dropped.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parenthetical content appears in any of the four spans.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	The ER states “No risk reaches High”, and line 577 correctly renders risks_high as an empty span with style="display: none" rather than empty-state text.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Every row and the cadence come from the ER Monitoring Protocol & Defining Success section.
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All nine rows of the ER biomarker table are present, with name, target and why reproduced verbatim from the ER’s “Biomarker”, “Optimal Functional Range” and “Why Measure It?” columns.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Line 705 gives the full cadence — baseline with 14 days of readings, weekly blood pressure and sleep, cognitive screen at 8 weeks, blood panel at course end and at 6 months — matching the ER paragraph.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	All five entries come from the ER’s “Qualitative markers worth tracking alongside the laboratory values” list.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All five ER qualitative markers are present and reproduced verbatim in qualitative_item_1 through qualitative_item_5.

Issues 04/09/2026 21:06

Pass rate 100.00%. No issues found.

Issues 04/09/2026 20:57

1. 1.1 / 7.3 — At-a-glance overstates untested claim: [at_a_glance] (line 433) says Noopept “has never been tested in people with normal thinking”, but the ER describes a controlled trial in healthy volunteers aged 20 to 24 (ER line 162) and makes only the narrower claim that no study measured thinking in unimpaired people (ER line 395).
2. 1.3 / 2.5 — Evening-dosing clause reads as a directive: [action_2_sub] (line 461) reduces the ER’s “the activating electroencephalography signature argues against dosing within eight hours of bedtime” (ER line 307) to “not within eight hours of bedtime”, turning a hedged inference into prescriptive advice.

Fixes 04/09/2026 20:57

1. 1.1 / 7.3 — At-a-glance untested claim narrowed: Replaced “and it has never been tested in people with normal thinking” with “and no study has measured thinking in people who were unimpaired”, matching the ER Conclusion and no longer contradicting the healthy-volunteer trial. At-a-glance remains at 59 words.
2. 1.3 / 2.5 — Evening-dosing clause de-prescribed: Replaced the directive fragment “not within eight hours of bedtime” in [action_2_sub] with “the activating brain-rhythm signature argues against dosing within eight hours of bedtime”, restoring the ER’s hedged framing.